Average Co-Inventor Count = 2.93
ph-index = 9
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Alcon Research, Ltd. (10 from 346 patents)
2. Alcon, Inc. (9 from 1,167 patents)
3. Alcon Laboratories, Inc. (8 from 449 patents)
4. Arrowhead Pharmaceuticals, Inc. (4 from 95 patents)
5. Alcon Universal Ltd. (3 from 71 patents)
6. Arrowhead Research Corporation (2 from 18 patents)
7. Other (1 from 832,680 patents)
8. Kalypsys, Inc. (1 from 17 patents)
9. John M. Yanni (0 patent)
10. Steven T. Miller (0 patent)
11. Ltd. Alcon Manufacturing (0 patent)
12. Jon E. Chatterton (0 patent)
13. Daniel A. Gamache (0 patent)
38 patents:
1. 9765340 - RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of CAMP-related ocular disorders
2. 9745585 - RNAi-mediated inhibition of histamine receptor H1-related conditions
3. 9533053 - High concentration olopatadine ophthalmic composition
4. 9453220 - RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
5. 9447419 - RNAi-mediated inhibition of tumor necrosis factor α-related conditions
6. 9371529 - RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
7. 9206428 - RNAi-mediated inhibition of histamine receptor H1-related conditions
8. 8865671 - RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions
9. 8791154 - High concentration olopatadine ophthalmic composition
10. 8673873 - RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
11. 8618278 - RNAi-mediated inhibition of histamine receptor H1-related conditions
12. 8541389 - RNAi-mediated inhibition of tumor necrosis factor α-related conditions
13. 8222227 - RNAi-mediated inhibition of histamine receptor H1-related conditions
14. 8138205 - Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
15. 8048863 - RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions